2023
Commentary: Mania in Medically Ill Patients
Garakani A. Commentary: Mania in Medically Ill Patients. Journal Of Psychiatric Practice 2023, 29: 426-427. PMID: 37678372, DOI: 10.1097/pra.0000000000000731.Commentaries, Editorials and LettersConceptsBipolar disorderBehçet's diseasePatient's symptomsManic symptomsMedical settingsMedically Ill PatientsComprehensive medical evaluationPrimary bipolar disorderSecondary maniaIll patientsMedical illnessMedical floorPsychiatric providersCase reportThorough historyEmergency roomEmergency settingMedical evaluationPsychiatric consultationPsychiatric treatmentPatientsFrontal lobeSymptomsDiseaseDisorders
2022
Commentary: Psychiatric Symptoms Related to Somatic Illness
Garakani A. Commentary: Psychiatric Symptoms Related to Somatic Illness. Journal Of Psychiatric Practice 2022, 28: 514-515. PMID: 36355593, DOI: 10.1097/pra.0000000000000674.Commentaries, Editorials and LettersConceptsAuditory hallucinationsVisual hallucinationsPsychiatric historySomatic illnessPatient's psychiatric historySemicircular canal dehiscencePsychosis presentPsychiatric consultation serviceCharles Bonnet syndromeCanal dehiscenceHypertensive episodesCases of hallucinationsPsychiatric symptomsPsychotic symptomsPsychotic disordersProper diagnosisMedical providersPatientsMedical teamSymptomsConsultation serviceHallucinationsThought disorderIllnessDisordersCommentary: Futility in Psychiatry
Garakani A. Commentary: Futility in Psychiatry. Journal Of Psychiatric Practice 2022, 28: 349-350. PMID: 35797694, DOI: 10.1097/pra.0000000000000649.Commentaries, Editorials and Letters
2021
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
Garakani A. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. Journal Of Psychiatric Practice 2021, 27: 496-497. PMID: 34768276, DOI: 10.1097/pra.0000000000000593.Commentaries, Editorials and LettersConceptsTreatment-resistant depressionElectroconvulsive therapyLiver transplantationChronic treatment-resistant depressionUse of ECTMaintenance electroconvulsive therapyMajor depressive episodeBitemporal treatmentsIntranasal formsIntranasal ketaminePartial responsePrescribed antipsychoticsAdjunctive treatmentAntirejection medicationsChronic migraineMigraine medicationsECT treatmentComorbid migraineDepressive episodePsychotic featuresOrgan transplantationKetamine abuseBrain stimulationClinical considerationsPatientsSelective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequencesCommentary: Psychiatric Presentations of Nonpsychiatric Illness or Treatment
Garakani A. Commentary: Psychiatric Presentations of Nonpsychiatric Illness or Treatment. Journal Of Psychiatric Practice 2021, 27: 404-405. PMID: 34529609, DOI: 10.1097/pra.0000000000000577.Commentaries, Editorials and LettersConceptsManic symptomsPsychiatric historyPerinatal brain injuryOff-label useExamples of patientsPsychogenic nauseaRefractory nauseaGastroesophageal refluxAtypical presentationMood stabilizersSubdural hematomaCertain patientsMedical historyPsychiatric presentationsBrain injuryVisual hallucinationsMedical disordersPsychiatric symptomsPatientsNonpsychiatric illnessCognitive deficitsSuicidal thinkingSymptomsTraditional treatmentBrain imagingIntensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders
Buono FD, Larkin K, Rowe D, Perez-Rodriguez MM, Sprong ME, Garakani A. Intensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders. Frontiers In Psychology 2021, 12: 629842. PMID: 34497550, PMCID: PMC8419465, DOI: 10.3389/fpsyg.2021.629842.Peer-Reviewed Original ResearchSubstance use disordersBorderline personality disorderComorbid substance use disorderUse disordersDialectical behavioral therapyTreatment programComorbid borderline personality disorderPersonality disorderDepression symptom scaleModerate depression scoresDepressive symptomsGroup 2Depression scoresGroup 1Symptom ScaleDBT treatmentSymptom overlapUnivariate general linear modelBehavioral therapyDisordersSignificant decreaseBehavior treatmentGeneral linear modelSignificant differencesPatientsCommentary: Diagnostic and Treatment Issues in Psychosis
Garakani A. Commentary: Diagnostic and Treatment Issues in Psychosis. Journal Of Psychiatric Practice 2021, 27: 338-339. PMID: 34398586, DOI: 10.1097/pra.0000000000000562.Commentaries, Editorials and LettersConceptsPsychotic symptomsUse of intranasalWide differential diagnosisFirst-episode schizophreniaMore common conditionsRare presentationPostpartum periodDifferential diagnosisPsychotic episodeCommon conditionSymptomsTreatment issuesPeriodic catatoniaPatientsFirst caseThird caseDiagnosisTreatmentBroad spectrumCommentary: Diagnostic Challenges in Evaluating Adolescents
Garakani A. Commentary: Diagnostic Challenges in Evaluating Adolescents. Journal Of Psychiatric Practice 2021, 27: 239-240. PMID: 33939380, DOI: 10.1097/pra.0000000000000553.Commentaries, Editorials and LettersConceptsDiagnostic challengeConstellation of symptomsProminent mood symptomsPosttraumatic stress disorderFemale patientsTrauma-related symptomsMedication treatmentAntipsychotic medicationAdolescent patientsUnnecessary treatmentVisual hallucinationsDifferential diagnosisPatient reportsTerms of stigmaMood symptomsDepressive symptomsPsychotic symptomsSide effectsPatientsPsychotic disordersSuicidal ideasFull differential diagnosisAuditory hallucinationsCotard's syndromeIncorrect diagnosis
2020
Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm.
Garakani A, Buono FD, Marotta RF. Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm. Journal Of Clinical Psychopharmacology 2020, 40: 507-509. PMID: 32701906, DOI: 10.1097/jcp.0000000000001248.Peer-Reviewed Case Reports and Technical NotesChronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital
Buono FD, Savage SR, Cerrito B, O’Connell J, Garakani A, Ackerman S, Cutter CJ. Chronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital. Journal Of Pain Research 2020, 13: 1515-1523. PMID: 32612379, PMCID: PMC7322115, DOI: 10.2147/jpr.s250568.Peer-Reviewed Original ResearchPain severityPsychiatric hospitalChronic Pain Coping InventoryChronic pain programRetrospective chart reviewOpioid use disorderPain Coping InventorySpecific psychiatric disordersCo-occurring disordersPsycho-behavioral therapySignificant differencesPain reliefChart reviewAnalgesic opioidsPain programChronic painPain interferenceInterdisciplinary careMedication managementMood disordersPain copingPsychiatric disordersUse disordersOpioidsPatients
2019
Pharmacogenomic Testing in Psychiatry: Ready for Primetime?
Rakesh G, Sumner CR, Alexander JL, Gross LS, Pine J, Slaby A, Garakani A, Baron D. Pharmacogenomic Testing in Psychiatry: Ready for Primetime? The Journal Of Nervous And Mental Disease 2019, 208: 127-130. PMID: 31895226, DOI: 10.1097/nmd.0000000000001107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Opinions Regarding Benzodiazepine Teaching and Prescribing Among Trainees in Psychiatry
Garakani A, Abdullah HM, Chang CM, Mendelsohn N, Lapidus KAB. Opinions Regarding Benzodiazepine Teaching and Prescribing Among Trainees in Psychiatry. Academic Psychiatry 2017, 42: 297-303. PMID: 28685349, DOI: 10.1007/s40596-017-0750-0.Peer-Reviewed Original Research
2016
Sleep‐Wake Disorders
Shenoy A, Fischer R, Garakani A. Sleep‐Wake Disorders. 2016, 207-216. DOI: 10.1002/9781118654231.ch23.ChaptersNeuropsychiatric aspects of concussion
Radhakrishnan R, Garakani A, Gross LS, Goin MK, Pine J, Slaby AE, Sumner CR, Baron DA. Neuropsychiatric aspects of concussion. The Lancet Psychiatry 2016, 3: 1166-1175. PMID: 27889010, DOI: 10.1016/s2215-0366(16)30266-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTraumatic brain injuryBrain injuryDirect head traumaProspective clinical trialsEffective treatment interventionsNon-contact sportsHistory of lossHead traumaNeuropsychiatric symptomsPatient populationPsychiatric morbidityClinical trialsNeuropsychiatric aspectsTreatment responseElderly individualsContact sportsReliable biomarkersPsychiatric cliniciansTreatment interventionsClinical phenotypeConcussionMild formRelevant outcomesInjuryPatients
2015
Heart rate and respiratory response to doxapram in patients with panic disorder
Martinez JM, Garakani A, Aaronson CJ, Gorman JM. Heart rate and respiratory response to doxapram in patients with panic disorder. Psychiatry Research 2015, 227: 32-38. PMID: 25819170, PMCID: PMC4420657, DOI: 10.1016/j.psychres.2015.03.001.Peer-Reviewed Original ResearchConceptsPD patientsLF/HFPanic disorderHealthy controlsAnticipatory anxietyPD subjectsParasympathetic componentRespiratory responsesLF/HF ratioSensation of dyspneaHeart rate variability indicesHigher sympathetic activityInjection of salinePanic statesSympathetic activityRespiratory abnormalitiesBrain stemRespiratory stimulantHeart rateParasympathetic responsePanic attacksPatientsExaggerated fear responsePanic symptomsHF ratio
2013
Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse
Leibu E, Garakani A, McGonigle DP, Liebman LS, Loh D, Bryson EO, Kellner CH. Electroconvulsive Therapy (ECT) for Catatonia in a Patient With Schizophrenia and Synthetic Cannabinoid Abuse. Journal Of Ect 2013, 29: e61-e62. PMID: 23670023, DOI: 10.1097/yct.0b013e318290fa36.Peer-Reviewed Case Reports and Technical NotesTransient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder
Majeske MF, Garakani A, Maloutas E, Bryson EO, Kellner CH. Transient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder. Journal Of Ect 2013, 29: e63-e65. PMID: 23774055, DOI: 10.1097/yct.0b013e3182972b8c.Peer-Reviewed Case Reports and Technical NotesConceptsElectroconvulsive therapyECT treatmentManic symptomsIntellectual disabilityBipolar disorderUse of ECTAdditional ECT treatmentsMultiple medication trialsTransient febrile reactionMild-moderate intellectual disabilityFever workupTransient feverMedication trialsFebrile reactionsPressured speechManic statePatient's motherPsychiatric disordersPatientsYoung adultsDisordersFeverTreatmentTherapySymptomsA Case of Reversible Neuropsychiatry Symptoms in HIV due to Toxic Leukoencephalopathy.
Liu MC, Garakani A, Krauskopf KA, Robinson-Papp J. A Case of Reversible Neuropsychiatry Symptoms in HIV due to Toxic Leukoencephalopathy. Innov Clin Neurosci 2013, 10: 26-9. PMID: 24307979, PMCID: PMC3849875.Peer-Reviewed Case Reports and Technical NotesToxic leukoencephalopathyHuman immunodeficiency virus (HIV) infectionMothball ingestionCentral nervous system white matterNervous system white matterNumerous potential etiologiesImmunodeficiency virus infectionHuman immunodeficiency virusNeuropsychiatry symptomsClinical presentationClinical findingsImmunodeficiency virusNeuropsychiatric syndromePotential etiologiesVirus infectionLeukoencephalopathyCocaine abuseWhite matterCognitive declineSubstance abuseIngestionAbuseMagnetic resonanceHIVPatientsOphthalmologic Screening in 25 Consecutive Geriatric Psychiatric Inpatient Admissions
Billick SB, Garakani A. Ophthalmologic Screening in 25 Consecutive Geriatric Psychiatric Inpatient Admissions. Psychiatric Quarterly 2013, 85: 49-56. PMID: 23963654, DOI: 10.1007/s11126-013-9269-z.Peer-Reviewed Original ResearchConceptsOphthalmologic screeningAge-related macular degenerationGeriatric psychiatric patientsPsychiatric inpatient admissionsRisk of fallsGeneral physical examinationGeriatric psychiatric inpatientsInpatient psychiatric unitAccurate differential diagnosisQuality assurance reviewGeriatric patientsInpatient admissionsPhysical examinationMacular degenerationDifferential diagnosisVisual abnormalitiesChart documentationOphthalmic problemsPsychiatric unitPsychiatric patientsPsychiatric treatmentPatientsRetinal defectsPsychiatric inpatientsVisual problems